# US 2023/0056336 A1 · Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056336 A1
- Document ID: US20230056336A1
- Status: Published application
- Kind: A1
- Application number: 17/721,927
- Filed: 2022-04-15
- Published: 2023-02-23
- Earliest claimed: 2021-04-15
- Applicants: Kyverna Therapeutics, Inc.
- Inventors: Lih-Yun Hsu; Faye Wu; Jeffrey Greve; Erin O'Brien; Jeanne Flandez; John Lee
- Web page: https://patentgrep.com/patent/US20230056336A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4242: {Transcription factors, e.g. SOX or c-MYC}
- A61P 37/02: Immunomodulators
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 14/7155: {for interleukins [IL]}
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This document relates to methods and materials for treating a mammal having an autoimmune disease. For example, materials and methods for producing a T cell comprising a FOXP3 polypeptide and a cellular suicide agent are provided herein. Methods and materials for treating a mammal having an autoimmune disease comprising administering to a mammal having an autoimmune disease an effective amount of a T cell are also provided herein.

## Claims

### Claim 1

A T cell comprising:
a first nucleic acid sequence encoding a FOXP3 polypeptide; and
a second nucleic acid sequence encoding a cellular suicide agent.

### Claim 2 (depends on 1)

The T cell of claim 1, wherein the first nucleic acid sequence encoding a FOXP3 polypeptide comprises a mutation in exon 2, wherein the FOXP3 polypeptide comprising a mutation in exon 2 results in increased nuclear localization of the FOXP3 polypeptide as compared to a FOXP3 polypeptide comprising an exon 2 that does not include a mutation.

### Claim 3 (depends on 2)

The T cell of claim 2, wherein the mutation comprises deletion of exon 2.

### Claim 4 (depends on 1)

The T cell of claim 1, wherein the cellular suicide agent is a CD25 polypeptide.

### Claim 5 (depends on 4)

The T cell of claim 4, wherein the CD25 polypeptide is a mutant CD25 polypeptide, wherein the mutant CD25 polypeptide comprises one or more amino acid substitutions, insertions, or deletions as compared to a wild type CD25 polypeptide.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The T cell of claim 5, wherein the mutant CD25 polypeptide comprises one or more amino acid substitutions selected from the group consisting of: L42A, L42W, L2F, L42G, Y43R, L2Y, L42Y, L2I, T47D, S41N, L42V, T47S, S41Q, S41E, S41D, L42F, T47N, and L42I.

### Claim 8 (depends on 7)

The T cell of claim 7, wherein the mutant CD25 polypeptide comprises a L42A amino acid substitution.

### Claim 9 (depends on 7)

The T cell of claim 7, wherein the mutant CD25 polypeptide comprises a L42W amino acid substitution.

### Claim 10 (depends on 7)

The T cell of claim 7, wherein the mutant CD25 polypeptide comprises a L2I amino acid substitution.

### Claim 11 (depends on 7)

The T cell of claim 7, wherein the mutant CD25 polypeptide comprises a Y43R amino acid substitution.

### Claim 12 (depends on 7)

The T cell of claim 7, wherein the mutant CD25 polypeptide comprises a L2F amino acid substitution.

### Claim 13 (depends on 7)

The T cell of claim 7, wherein the mutant CD25 polypeptide comprises a L42G amino acid substitution.

### Claim 14 (depends on 7)

The T cell of claim 7, wherein the mutant CD25 polypeptide comprises a L2Y amino acid substitution.

### Claim 15 (depends on 7)

The T cell of claim 7, wherein the mutant CD25 polypeptide comprises a L42Y amino acid substitution.

### Claim 16 (depends on 5)

The T cell of claim 5, wherein the mutant CD25 polypeptide has increased affinity for basiliximab as compared to a wild type CD25 polypeptide.

### Claim 17 (depends on 1)

The T cell of claim 1, wherein the first nucleic acid sequence is operably linked to a promoter and the second nucleic acid sequence is operably linked to a promoter.

### Claim 18 (depends on 1)

The T cell of claim 1, wherein the T-cell further comprises a third nucleic acid sequence encoding a receptor polypeptide, and wherein the third nucleic acid sequence is operably linked to a promoter.

### Claim 19

(canceled)

### Claim 20 (depends on 18)

The T cell of claim 18, wherein the receptor polypeptide is a chemokine receptor polypeptide comprising one of CCR6, CCR9, or GRP15.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The T cell of claim 1, wherein the T cell further comprises a nucleic acid sequence encoding a binding agent, wherein the nucleic acid sequence encoding the binding agent is operably linked to a promoter.

### Claim 23

(canceled)

### Claim 24 (depends on 22)

The T cell of claim 22, wherein the binding agent comprises an antigen-binding domain selected from the group consisting of: a Fab, a F(ab′)2 fragment, a scFV, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody.

### Claim 25 (depends on 22)

The T cell of claim 22, wherein the binding agent is a chimeric antigen receptor, wherein the chimeric antigen receptor comprises an extracellular domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain comprises an antigen-binding domain capable of binding to an antigen on an autoimmune cell, and wherein the intracellular domain comprises a cytoplasmic signaling domain and one or more co-stimulatory domains.

### Claim 26 (depends on 25)

The T cell of claim 25, wherein the antigen-binding domain is a scFv that is capable of binding to the antigen on the autoimmune cell.

### Claim 27 (depends on 25)

The T cell of claim 25, wherein the cytoplasmic signaling domain is a CD3 zeta domain and the co-stimulatory domain comprises at least one of a CD48 domain, a 4-1BB domain, an ICOS domain, an OX40 domain, and a CD27 domain.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

A composition comprising a T cell of claim 1.

### Claim 30 (depends on 1)

A method of producing a T-cell population expressing an exogenous FOXP3 polypeptide and a cellular suicide agent, the method comprising culturing a T-cell of claim 1 in growth media under conditions sufficient to expand the population of T-cells.

### Claim at position 31

-32. (canceled)

### Claim 33

A vector comprising:
a first nucleic acid sequence encoding a FOXP3 polypeptide; and
a second nucleic acid sequence encoding a cellular suicide agent.

### Claim at position 33

-35. (canceled)

### Claim 36 (depends on 33)

The vector of claim 33, wherein the cellular suicide agent is a CD25 polypeptide, wherein the mutant CD25 polypeptide comprises one or more amino acid substitutions selected from the group consisting of: L42A, L42W, L2F, L42G, Y43R, L2Y, L42Y, L2I, T47D, S41N, L42V, T47S, S41Q, S41E, S41D, L42F, T47N, and L42I.

### Claim at position 35

-66. (canceled)

### Claim 67 (depends on 1)

A method of treating a subject, wherein the method comprising:
administering to the subject a T cell of claim 1; and
after a period of time, administering to the subject an effective amount of a control agent capable of interacting with a cellular suicide agent, wherein the interaction between the control agent and the cellular suicide agent reduces the number of administered T cells in the subject.

### Claim at position 37

-76. (canceled)

### Claim 77

A method of reducing the number of administered T cells in a subject, the method comprising:
administering to the subject an effective amount of a control agent capable of interacting with a cellular suicide agent, wherein the interaction between the control agent and the cellular suicide agent reduces the number of administered T cells in the subject.

### Claim at position 39

-81. (canceled)
